Baudax Bio (Baudax Bio) Float Percentage Of Total Shares Outstanding : 99.99% (As of May. 01, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Baudax Bio Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Baudax Bio's float shares is 43.58 Mil. Baudax Bio's total shares outstanding is 43.59 Mil. Baudax Bio's float percentage of total shares outstanding is 99.99%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Baudax Bio's Insider Ownership is 1.89%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Baudax Bio's Institutional Ownership is 0.00%.

Baudax Bio Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Baudax Bio's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	43.58	/	43.59
	=	99.99%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Baudax Bio (Baudax Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Baudax Bio Inc (OTCPK:BXRXQ) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

490 Lapp Road, Malvern, PA, USA, 19355

Website

https://www.baudaxbio.com

Baudax Bio Inc is a Pharmaceutical company. The company develops and commercialize products for hospital and related acute care settings. Its products are in pipeline which includes two novel neuromuscular blocking agents, or NMBAs.

Executives

Natalie Mcandrew	officer: Interim CFO	C/O BAUDAX BIO, INC., 490 LAPP ROAD, MALVERN PA 19355
Yong Chan Kim	director	C/O BAUDAX BIO, INC., 490 LAPP ROAD, MALVERN PA 19355
Winston J Churchill	director	C/O SCP PARTNERS, SUITE 300, 1200 LIBERTY RIDGE DRIVE, WAYNE PA 19087
William Ashton	director	C/O HARRISON CONSULTING GROUP, PO BOX 283, NEWTOWN SQUARE PA 19073
Andrew T Drechsler	director	10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Arnold M Baskies	director	1235 SEQUOIA ROAD, CHERRY HILL NJ 08003
Wayne Weisman	director	490 LAPP ROAD, MALVERN PA 19355
Jillian Dilmore	officer: Corporate Controller/Secretary, other: PFO and PAO	C/O BAUDAX BIO, INC., 490 LAPP ROAD, MALVERN PA 19355
Geraldine Henwood	director, officer: President and CEO	88 SIDNEY ST, CAMBRIDGE MA 02139
Richard S Casten	officer: Chief Financial Officer	490 LAPP ROAD, MALVERN PA 19355
Alfred Altomari	director	C/O AGILE THERAPEUTICS, INC., 101 POOR FARM ROAD, PRINCETON NJ 08540
Ryan David Lake	director, officer: Chief Financial Officer	KENSEY NASH CORPORATION, 735 PENNSYLVANIA DRIVE, EXTON PA 19341
Recro Pharma, Inc.	10 percent owner	1 E. UWCHLAN AVE, SUITE 112, EXTON PA 19341